Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CLDI |
---|---|---|
09:32 ET | 28639 | 0.1601 |
09:34 ET | 44500 | 0.1635 |
09:36 ET | 790 | 0.1607 |
09:38 ET | 704 | 0.161 |
09:45 ET | 1600 | 0.161961 |
09:48 ET | 7668 | 0.1649 |
09:56 ET | 3057 | 0.1615 |
09:57 ET | 50000 | 0.161 |
10:01 ET | 130 | 0.161 |
10:06 ET | 2700 | 0.161 |
10:19 ET | 1700 | 0.1621 |
10:30 ET | 800 | 0.1621 |
10:37 ET | 10000 | 0.162129 |
10:39 ET | 400 | 0.1622 |
10:44 ET | 100 | 0.162 |
10:46 ET | 3475 | 0.1647 |
10:48 ET | 500 | 0.165 |
10:51 ET | 1041 | 0.165 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Calidi Biotherapeutics Inc | 5.7M | -0.3x | --- |
HST Global Inc | 5.8M | -29.1x | --- |
Kintara Therapeutics Inc | 5.8M | 0.0x | --- |
Goldenwell Biotech Inc | 5.8M | -48.0x | --- |
Burzynski Research Institute Inc | 5.6M | -4.7x | --- |
Creative Medical Technology Holdings Inc | 5.9M | -1.2x | --- |
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.63 |
Book Value | $-0.90 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.